Barclays PLC Point Biopharma Global Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$6.67 - $9.71 $180,290 - $262,461	27,030 Added 23.46%	142,257 $949,000
Q2 2023 Aug 03, 2023	BUY	$6.86 - $10.86 $97,885 - $154,961	14,269 Added 14.13%	115,227 $1.04 Million
Q1 2023 May 04, 2023	SELL	$6.78 - $8.1 $525,721 - $628,074	-77,540 Reduced 43.44%	100,958 $735,000
Q4 2022 Feb 13, 2023	BUY	$5.72 - $9.78 $478,735 - $818,537	83,695 Added 88.28%	178,498 $1.3 Million
Q3 2022 Nov 03, 2022	BUY	$7.24 - $10.31 $562,359 - $800,818	77,674 Added 453.46%	94,803 $733,000
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $19,885 - $33,734	3,551 Added 26.15%	17,129 $116,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $74,135 - $110,389	13,578 New	13,578 $108,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.